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E-mail address: patricia.woo@ucl.ac.uk (P. Woo).The MAPK/ERK signalling pathway has been described to mediate IL-1 induction of target genes and
is known to be regulated by microRNAs (miRNA). We describe a novel miRNA regulating the expres-
sion of the MEK1 gene and how it impacts IL-1 induced IL-6 transcription. miR-497 was predicted to
target MEK1 30UTR using bioinformatic tools. Transfection of miR-497 into HeLa cells inhibited
MEK1 protein expression by 50%. In transient transfection experiments, the luciferase activity of a
MEK1 30UTR luciferase reporter construct was reduced in the presence of miR-497, and mutation
of the predicted miR-497 binding site restored activity. miR-497 also decreased protein levels of
RAF1 and ERK1 but not ERK2. Addition of miR-497 was further shown to inhibit IL-1 induced IL-6
gene transcription.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction arily conserved signal transduction cascade involved in the controlInterleukin 1 (IL-1) is a key pro-inﬂammatory cytokine that
mediates the expression of multiple genes, thereby contributing
to immune and inﬂammatory responses. Dysregulation of the nor-
mal expression patterns of IL-1 and/or its target genes is central in
the pathology of autoimmune and auto-inﬂammatory diseases.
Relatively little is known regarding the control of the intracellular
signalling pathways once an IL-1 signal is received. IL-1 signals via
its Type I receptor through the mitogen-activated protein kinase
(MAPK) signalling pathways leading to activation of transcription
factors, such as NFjB (nuclear factor jB) and AP-1 (activator pro-
tein 1), which then activate multiple genes such as IL-6 and IL-8
[1,2]. There are at least three distinct and parallel MAPK pathways
involved: extracellular signal-regulated kinase (ERK), c-Jun
amino-terminal kinase (JNK), and p38. The ERK pathway is usually
considered as the ‘classic’ MAPK signalling pathway in which RAF1
(v-raf-1 murine leukaemia viral oncogene homolog 1) mediates
phosphorylation of MEK1/2 (MAP kinase kinases 1 and 2), which
in turn mediate phosphorylation of ERK1/2 [2]. It is an evolution-chemical Societies. Published by E
ivated protein kinase; NFjB,
xtracellular signal-regulated
gen-activated protein kinase
e leukaemia viral oncogene
realtime polymerase chainof many fundamental cellular processes that lead to cell prolifera-
tion, apoptosis, and differentiation.
The control of the expression of these signalling molecules is
therefore one of the important steps in transmission of the IL-1 sig-
nal within the cell. MicroRNAs (miRNAs) have been observed to
regulate the ERK pathway at posttranscriptional level. miRNAs
are a class of 19–24 nucleotide long non-coding RNAs that have
been regarded as important posttranscriptional regulators of cell
differentiation, apoptosis, and proliferation, as well as the immune
response [3]. They regulate gene expression by forming imperfect
base pairing with sequences in the 30 untranslated region (30UTR)
of their target mRNAs, leading to mRNA degradation, or inhibition
of translation into protein [4]. The 2–8 nucleotides of a miRNA,
called the ‘‘seed region’’, are often important for base pairing [5].
It has been shown that miRNA let-7 negatively regulates RAS
genes, the upstream signalling molecules of RAF1 in the ERK path-
way [6,7]. RAF1 is targeted by miR-497 and miR-125b [8,9]. How-
ever, little is known about miRNA control of MEK1 and MEK2
protein expression. In ﬁbroblast cells MEK1 but not MEK2 forms
a signalling complex with RAF1 which suggests that in those cells
the RAF1 signalling pathway preferentially activates ERKs via
MEK1 [10]. We have provided novel evidence in this study that hu-
man miR-497 negatively regulates expression of MEK1 in HeLa
cells by classic interaction with the MEK1 30UTR and represses its
mRNA translation. We conﬁrmed that miR-497 also targets RAF1
and ERK1, and could impact on inﬂammatory responses by
affecting IL-1b signalling.lsevier B.V. All rights reserved.
Table 1
Primer sequences used in this study.
Forward (50 ? 30) Reverse (50 ? 30)
Cloning
MEK1-fulla CCGCTCGAGAAGTGGATTTTGCAGGTTGG ATTTGCGGCCGCTGGTACTTGGATATGGGGAAA
MEK1-shorta CCGCTCGAGTGCCTGTATTTTCGGGATTC ATTTGCGGCCGCCAGCTATCATGGCAGTGAA
Mutagenesis
Mut1b CAGTGCATGTGAAGCATGCTTTGGACGTATGAAA ATGAGCATCAGAGAGT ACTCTCTGATGCTCATTTTCATACGTCCAAAGCAT GCTTCACATGCACTG
Mut2b CCAGCACACCAACCCATGGACGTGGCGTCTAAGT GTTTGG CCAAACACTTAGACGCCACGTCCATGGGTTGGTG TGCTGG
a Italicised regions indicate the position of restriction enzyme target sequence.
b Underlined regions indicate the positions of mutation.
Table 2
MiRNAs predicted to target MEK1 (MAP2K1).
aPositions of seed sequence are relative to the start of the MEK1 30UTR.
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Fig. 1. The effect of miR-497 on MEK1 expression. (A) MEK1 mRNA expression
measured by qPCR. HeLa cells were transfected with 10 nM of miRNA precursors
alone or in combination of miRNA inhibitor (anti-497) for 48 h and then collected
for RNA puriﬁcation and qPCR analysis. The measurements were normalised to
those for the RPLP0 gene before being compared to control. miNeg: miRNA
precursor negative control (B) Western blot image of MEK1 protein expression. The
image is a representative of three separate experiments. miNeg: miRNA precursor
negative control; antiNeg: anti-miR negative control. (C) Quantiﬁcation of MEK1
protein levels in Western blot analysis. Cell lysates from treated cells described
above were subjected to immunoblotting with antibody against MEK1 or GAPDH.
The protein bands were quantiﬁed by ImageJ (NIH) and normalised to those of
GAPDH bands before compared to those measured in miNeg#1-transfected cells
(= 1.0). The values are the mean and S.D. from three experiments. ⁄P < 0.05
compared to control cells.
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2.1. Prediction of candidate miRNAs binding to MEK1 30UTR
Three software applications were used to predict potential miR-
NAs targeting the MEK1 30UTR: TargetScan 6.1 [11,12], miRANDA
[13] and PITA [14]. To maximise our chances of ﬁnding real candi-
dates, only those miRNA target sites predicted by all three pro-
grams and broadly conserved among vertebrates were considered.
2.2. Cell culture and miRNA transfection
HeLa cells were maintained in DMEM supplemented with 10%
FBS in a 37 C incubator with 5% CO2.
For miRNA transfection, cells were plated in 24-well plates and
incubated for 24 h before transfection. Near conﬂuent cells were
transfected with 10 nM of precursor of microRNA (pre-miR, Ap-
plied Biosystems) or 10 nM pre-miR in combination with 50 nM
miR inhibitor (anti-miR, Applied Biosystems) using Lipofectamine
RNAiMAX (Invitrogen) according to the manufacturer’s protocol.
Cells were collected for RNA and protein analysis at 48 h after
transfection.
For IL-1 stimulation, HeLa cells were transfected with miRNAs
for 36 h and then incubated in DMEM plus 2% FBS for 12 h,
followed by addition of 0.5 ng/ml of IL-1b (Sigma). Cells were
collected at 0, 5 min, 15 min, 30 min and 1 h for protein analysis,
at 0, 1 h, 3 h, 6 h, 14 h, 24 h for RNA analysis.
2.3. RNA puriﬁcation and quantitative real-time PCR (qPCR)
Total RNA was extracted using Trizol reagent (Invitrogen)
according to the manufacturer’s protocol. One microgram of RNA
was transcribed into cDNA using Qantitect reverse transcription
kit (Qiagen) and qPCR reactions were set up with Taqman gene
expression assays (Applied Biosystems) and Solaris qPCR Gene
Expression Master Mix (Thermal Scientiﬁc). The qPCR reactions
were performed on an Eppendorf Mastercycler with cycling condi-
tions as follows: 15 min of denaturation at 95 C and then 40 cycles
of 95 C for 15 s, 60 C for 1 min. The RPLP0 gene was used as an
endogenous control. Relative levels of mRNA expression of inter-
esting genes were calculated according to the DDCT method
[15], normalised by comparison to RPLP0 expression.
2.4. Western blot
Whole cell lysates were resolved by 10% NuPAGE Bis–Tris gel
(Invitrogen), transferred to a PVDF membrane (GE Healthcare).
The membrane was blocked with 5% bovine serum albumin (Sig-
ma) in tris-buffered saline and 0.1% Tween 20 and then incubated
with primary antibodies overnight at 4 C. The membranes were
then incubated with secondary HRP-conjugated antibodies at room
temperature and the proteins of interest were visualised with an
enhanced chemiluminescence detection system (Thermo
Scientiﬁc). The membranes were reprobed with antibody against
GAPDH to control for any loading differences between lanes. The
corresponding bands were quantiﬁed by image processing soft-
ware, ImageJ (NIH, http://rsb.info.nih.gov/ij/). The antibodies for
MEK1, p-MEK1, GAPDH, and secondary anti-mouse HRP IgG were
obtained from Santa Cruz Biotechnology. The antibodies for
ERK1/2, p-Erk1/2, RAF1, P38, p-P38 and anti-rabbit HRP IgG were
from Cell Signaling Technology.
2.5. 30UTR constructs, cotransfection and luciferase reporter assay
The full length and the short fragment of MEK1 30UTR sequence
were ampliﬁed from HeLa cDNA using primers incorporating XhoIand NotI cloning sites. The PCR fragments were then inserted into
the 30 end of the coding sequence of a Renilla luciferase gene in the
psiCheck-2 vector (Promega). Mutants were generated using a site-
directed mutagenesis protocol [16]. The oligonucleotides used in
this study are listed in Table 1. All constructs were conﬁrmed by
full sequencing.
For cotransfection, HeLa cells were seeded in 96-well plates and
cultured for 24 h before transfection with 50 ng of 30UTR construct
or empty vector using Lipofectamine LTX (Invitrogen). Six hours
after DNA transfection, cell media were replaced with fresh media
and then sequentially transfected with 10 nM of the miRNA pre-
cursors. Cell extracts were prepared 48 h after miRNA transfection.
Fig. 2. Validation of miR-497 target sites on MEK1. (A) Schematic structure of MEK1 30UTR constructs and putative miR-497 binding sites. The basepair positions labelled are
relative to the start of MEK1 30UTR. The sequence to be mutated is underlined. (B) Luciferase activities of the 30UTR constructs in miRNA transfected HeLa cells. The ratios of
Renilla:Fireﬂy luciferase activities were ﬁrst normalised to psiCHECK-2 and expressed as relative to the measurements from miNeg#1 transfected cells. Data shown are the
mean and S.D. of three separate experiments. ⁄P < 0.05 compared to control cells.
4168 D. Zheng et al. / FEBS Letters 586 (2012) 4165–4172The luciferase activities were measured with a Dual Luciferase
Assay System (Promega) and normalised to internal control Fireﬂy
luciferase activities. The luciferase activity of each construct was
compared with that of empty psiCHECK2 vector.
2.6. Statistic analysis
All experiments were repeated at least three times. Data are
presented as mean ± S.D. The statistical signiﬁcance of differences
between experimental groups was determined with two-tailed un-
paired Student’s t-test at a signiﬁcance level of P < 0.05.3. Results
3.1. miR-497 suppresses expression of MEK1 protein
Fourteen potential miRNA binding sites within the MEK1 30UTR
were predicted by TargetScan, miRANDA, and PITA programs and
belong to the miR-34, miR-15, miR-96 and miR-181 families
(Table 2). Of these candidates, miR-15a, -15b, -16, -424 and -497share the same ‘seed’ region and are from the miR-15 superfamily.
Many of the family members are associated with altered expres-
sion in cancers, neurodegeneration or autoimmune mouse models.
We focused on miR-497, the only miRNA within this list that has
been reported to be differentially expressed in CD4+ cells in a hu-
man autoimmune disease, multiple sclerosis [17].
To evaluate whether miR-497 affects MEK1 expression, HeLa
cells were transfected with the miR-497 precursor or the negative
control (miNeg#1) for 48 h and MEK1 mRNA and protein levels
were measured by qPCR and Western blots respectively. Although,
compared to miNeg#1 transfected cells, MEK1 mRNA expression
was marginally increased in the miR-497 transfected cells
(Fig. 1A), its protein expression was repressed by 50% (P < 0.05)
(Fig. 1B and C). The effect of miR-497 on MEK1 expression was re-
versed when miR497 was cotransfected with its speciﬁc inhibitor
anti-497 (Fig. 1B and C).
3.2. Veriﬁcation of the miR-497 target sites in the MEK1 30UTR
Computational analysis revealed a putative binding site (site1)
located at 449–470 bp of the MEK1 30UTR and the PITA program
Fig. 3. The effect of miR-497 on the ERK pathway. (A) Western blot images of total (t-) and phosphorylated (p-) protein expression of RAF1, MEK1 and ERK1/2 in miRNA
transfected cells described in Fig. 1. The intensities of protein bands were ﬁrst normalised to those of GAPDH bands and then compared to measurements from miNeg#1-
transfected cells. The relative levels are shown on the right. (B) Western blot images of total and phosphorylated protein levels in miRNA transfected cells following IL-1b
stimulation. After transfection with miRNAs for 48 h, HeLa cells were treated with 0.5 ng/ml IL-1b. Lysates were collected at 0, 5 min, 15 min, 30 min and 1 h of stimulation
and immunoblotted. The images are representatives of three independent experiments. (C) Quantiﬁcation of p-ERK2 and (D) p-ERK1 of Western blot images. The band
intensities were normalised to corresponding GAPDH bands and compared to those at time 0 in control cells. Data shown are the mean and S.D. ⁄P < 0.05 compared to
corresponding control.
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region (Fig. 2A). To validate these predictions, a luciferase reporter
construct containing a full length MEK1 30UTR at 30 end of a Renilla
luciferase gene was generated (psiMEK1-full) and the ‘‘seed’’
region of either site1 or site2 was mutated with a 4 bp substitution
(psiMEK1-fullmut1 and psiMEK1-fullmut2, respectively). The
wild-type or mutant constructs were cotransfected with the miR-
NA precursors into HeLa cells.
As shown in Fig. 2B 20% reduction in luciferase activity of the
wild-type reporter construct was observed when cotransfected
with miR-497 compared to control cells. Furthermore, while over-
expression of miR-497 still inhibited luciferase activity of psiM-
EK1-fullmut2, it had no signiﬁcant effect on the activity of
psiMEK1-fullmut1. Treatment with the miR-1226⁄ precursor,
which has no predicted target sites on MEK1 30UTR, did not affect
the luciferase activity of any reporter construct.
To minimise the interference from surrounding sequence, we
also generated a reporter construct containing a short 30UTR frag-
ment covering only site1 (psiMEK1-short). In agreement with re-
sults from full-length UTR, luciferase activity of psiMEK1-short
was repressed by 40% when cotransfected with miR-497, and the
inhibition was completely abolished when site1 was mutated.3.3. Effect of miR-497 on phosphorylation of MEK1 and other members
of the ERK pathway
In the MAPK/ERK cascade, RAF1 mediates phosphorylation of
MEK1, which in turn phosphorylates ERK1/2. To elucidate whether
the phosphorylation process is affected by miR-497, we measured
both total and phosphorylated protein levels of these proteins in
miRNA transfected cells. Phosphorylated (p-) MEK1 was reduced
to 63% of control levels in miR-497-transfected cells (Fig. 3A) while
total protein was reduced to 50% in Fig. 1. Interestingly, ERK1 and
ERK2, both of which are normally regulated similarly, showed dif-
ferential response. Transfection of miR-497 reduced t- and p-ERK1
levels to 62% and 64%, respectively, of expression in control cells
while neither ERK2 forms were signiﬁcantly changed. Consistent
with published literature, t-RAF1 level was signiﬁcantly inhibited
by miR-497 [18].
We next treated the miRNA transfected cells with 0.5 ng/ml of
IL-1b to examine their response to stimulus. As shown in Fig. 3B,
in cells transfected with either miR-497 or the control miNeg#1,
IL-1b had no effect on total protein levels of RAF1, MEK1 and
ERK1/2. Phosphorylation of MEK1 and ERK1/2 were induced by
IL-1b, reaching peak between 15 and 30 min after stimulation
Fig. 4. The effect of miR-497 on p38 activation. (A) Western blot images of total and phosphorylated p38 from IL-1b stimulation experiments measured at different time
points after addition of IL-1. (B) Quantiﬁcation of Western blot images of total protein t-p38/GAPDH from three separate experiments. (C) Quantiﬁcation of Western blot
images of phospho-p38 from three experiments. ⁄P < 0.05, comparison between cells transfected with miR-497 and its corresponding control transfected cells.
Fig. 5. Expression of IL-6 mRNA in miRNA-transfected cells following IL-1b
stimulation. Cells were transfected with miRNAs for 48 h, followed by the addition
of 0.5 ng/ml IL-1b and collected at different time points afterwards for qPCR
analysis. The data presented are mean and S.D. of fold changes from the basal level
at time 0.
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However, miR-497 transfected cells had notably less p-MEK1 and
p-ERK1 than control cells at all time points following IL-1b stimu-
lation while p-ERK2 did not seem to change (Fig. 3B and C). Further
quantitation indicated that not only were the maximum p-ERK1
levels lower in cells with miR-497 than in control cells, but also
dephosphorylation appeared to occur earlier, showing decline at
30 min (Fig. 3D).
3.4. Effect of miR-497 on p38 pathway
To see if there were also changes in the p38 pathway upon IL-1b
stimulation in miRNA transfected cells, we checked the levels of
t-p38 and p-p38 by Western blot. Total p38 levels were not signif-
icantly affected by introduction of miR-497 to HeLa cells before
and after IL-1beta stimulation (Fig. 4A and B), implying that p38
is not a direct target of miR-497. By contrast, phosphorylation of
p38 displayed a different response pattern between cells transfec-
ted with miR-497 and miNeg#1 (Fig. 4A and C). Relatively higher
levels of p-p38 were detected in miR-497-transfected cells at 5
and 15 min after stimulation, nearly twice the levels in corre-
sponding control cells. However, dephosphorylation of p38 already
occurred after 30 min of stimulation in miR-497 transfected cells
while its phosphorylation continued to be high in control cells. This
early dephosphorylation in miR-497 transfected cells mirrors what
occurred in the phosphorylation of ERK1 (Fig. 3D). At the end of
48 h of stimulation, p-p38 from both cells returned to similar
low levels.3.5. miR-497 affects IL-1-stimulated IL-6 gene transcription
Since IL-1b stimulates production of other cytokines, typically
IL-6, via p38 and ERK pathways in HeLa cells [19], it was relevant
to examine if miR-497 may inﬂuence IL-6 expression. As shown
in Fig. 5, IL-1 induction of IL-6 was signiﬁcantly repressed by
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was induced by 65-fold at 1 h in the control cells, dropped dramat-
ically to 23-fold at 3 h and then gradually decreased to less than
14-fold after 14 h until the end of the experiment at 24 h. By con-
trast, in the miR-497-transfected cells, IL-6 expression was induced
by only 13-fold and then decreased to and stayed at 5-fold after
3 h.4. Discussion
Many target prediction tools for miRNAs have been developed
based on a combination of stringency of miRNA:mRNA seed
pairing, site location, conservation, accessibility, and presence of
multiple sites. The sets of predicted target genes from different
tools do not overlap well [20]. We have applied three most fre-
quently used programs to predict miRNA regulators of the MEK1
gene. TargetScan considers seed pairing, target site location and
conservation; miRANDAweighs seed pairing as well as paring else-
where and also estimates site accessibility; PITA also considers the
seed pairing but estimates the free energy cost to unfold the miR-
NA:RNA structure. The combination of multiple programs can be
useful to narrow down candidates and increase the chance to ﬁnd
true regulators as demonstrated by this study.
We have shown experimentally that miR-497 is a negative reg-
ulator of MEK1 protein expression through directly binding to the
30UTR of the mRNA. Posttranscriptional regulation of MEK1 by
miRNA is not unique to miR-497. Recent studies showed that both
miR-1826 and miR-424 were negatively correlated with MEK1 pro-
tein levels [21,22].
Therefore MEK1 is subject to regulation by multiple miRNAs,
which may contribute to tissue or disease-speciﬁc modulation of
MEK1 activity.
Our results demonstrate for the ﬁrst time that miR-497 simul-
taneously inhibits protein levels of three members of the ERK path-
way, RAF1, MEK1 and ERK1. miR-497 along with miR-195 (also a
member of miR-15 family) have been shown by others to nega-
tively regulate RAF1 protein expression in breast cancer [9]. Lower
p-MEK1 seen in this study is likely to be a combined effect of low-
ered MEK1 and RAF1 protein levels induced by miR497. Lower
expression of p-ERK1/2 was also observed in this report but it
was regarded as the result of impairment of RAF1 activation. Our
results suggest that ERK1 may also be a target of miR-497 in HeLa
cells, consistent with an earlier study showing that miR-15 family
members targeted ERK1 30UTR in Neuro2a cells [23]. Since ERK2
phosphorylation has not been affected in our studies, the differen-
tial phosphorylation of ERK 1 and 2 observed is less likely to be the
upstream effect of miR-497 on RAF 1.The reduction of ERK1 phos-
phoproteins is more likely to be due to loss of total proteins. How-
ever, upon stimulation by IL-1b, we found not only lower induction
of ERK1 phosphorylation but also earlier dephosphorylation, thus
indicating that a more complex mechanism is involved.
Suppression with ERK or p38 pathway inhibitors reduces IL-1 or
TNF stimulated IL-6 expression [19,24], and this phenomenon is
also seen in our experiments where the actual fold increase of IL-
6 mRNA on IL-1 stimulation was reduced in the presence of trans-
fected miR497. Crosstalk between the ERK and p38 pathways has
been described [25,26], where inhibition of MEK1 activity by
MEK1 inhibitor, PD98059, resulted in an increase of p38 activity,
and vice versa. This may explain the higher p38 phosphorylation
levels following IL-1 stimulation in miR-497-transfected cells in
our study. It is evident that multiple levels of control of IL-1 intra-
cellular signalling by miRNAs already described [27–29] will need
further characterisation.
In the context of autoimmune diseases, an abnormal ERK
pathway in T lymphocytes is understood to play a part in initia-tion and progression of disease [30,31]. As a regulator of the ERK
pathway, miR-497 and other members of miR-15 family may
play important roles in the immune dysregulation observed in
these diseases. For example, miR-497 has been shown to be dif-
ferentially expressed in CD4 cells, CD8 cells and B cells in relaps-
ing-remitting multiple sclerosis (MS) patients compared to
healthy volunteers [17].
In summary, we have shown for the ﬁrst time that miR-497 is
one of the regulators of MEK1, in addition to RAF1, and plays a part
in modulating the inﬂammatory signal of IL-1 to one of its target
genes. Elucidating the role of microRNAs in regulating inﬂamma-
tory pathways may present us with an exciting new avenue in
autoimmune disease research.
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